Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® Clinical trial with AVA6103 is expected to be initiated ...

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells—so-called smart ...